rs12948217
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000049.4(ASPA):c.693C>A(p.Tyr231Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000416 in 1,612,170 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. Y231Y) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000049.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
ASPA | NM_000049.4 | c.693C>A | p.Tyr231Ter | stop_gained | 5/6 | ENST00000263080.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
ASPA | ENST00000263080.3 | c.693C>A | p.Tyr231Ter | stop_gained | 5/6 | 1 | NM_000049.4 | P1 | |
ASPA | ENST00000456349.6 | c.693C>A | p.Tyr231Ter | stop_gained | 6/7 | 1 | P1 | ||
SPATA22 | ENST00000541913.5 | c.-74+19004G>T | intron_variant | 2 | |||||
SPATA22 | ENST00000570318.1 | c.-74+19203G>T | intron_variant | 2 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 151980Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000557 AC: 14AN: 251370Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135864
GnomAD4 exome AF: 0.0000438 AC: 64AN: 1460190Hom.: 0 Cov.: 33 AF XY: 0.0000330 AC XY: 24AN XY: 726552
GnomAD4 genome AF: 0.0000197 AC: 3AN: 151980Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74214
ClinVar
Submissions by phenotype
Spongy degeneration of central nervous system Pathogenic:8Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 04, 2019 | NM_000049.2(ASPA):c.693C>A(Y231*) is classified as pathogenic in the context of Canavan disease. Sources cited for classification include the following: PMID 8023850. Classification of NM_000049.2(ASPA):c.693C>A(Y231*) is based on the following criteria: The variant causes a premature termination codon that is not expected to be targeted by nonsense-mediated mRNA decay; however, literature evidence strongly supports pathogenicity. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Oct 20, 2014 | The p.Tyr231X variant in ASPA has been reported in numerous individuals with Canavan disease (Kaul 1994) and is one of the most common disease-causing ASPA variants in the Ashkenazi Jewish population. It was absent from large population studies. This nonsense variant leads to a premature termination codon at position 231 which is predicted to lead to a truncated or absent protein. In summary, this variant meets our criteria to be classified as pathogenic for Canavan disease in an autosomal recessive manner. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 01, 1998 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Nov 14, 2023 | This sequence change creates a premature translational stop signal (p.Tyr231*) in the ASPA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ASPA are known to be pathogenic (PMID: 12638939). This variant is present in population databases (rs12948217, gnomAD 0.1%). This premature translational stop signal has been observed in individuals with Canavan disease (PMID: 8023850, 8659549, 10909858). It is commonly reported in individuals of Ashkenazi Jewish ancestry (PMID: 8023850, 8659549, 10909858). ClinVar contains an entry for this variant (Variation ID: 2609). For these reasons, this variant has been classified as Pathogenic. - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 07, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | The ASPA c.693C>A (p.Tyr231Ter) variant is a stop-gained variant and is predicted to terminate the protein prematurely. It has been reported in two studies and is found in a total of 13 individuals with Canavan disease including one in a homozygous state and 12 in a compound heterozygous state (Kaul et al. 1994; Kaul et al. 1996). All of the individuals except one were of Ashkenazi Jewish descent. Control data are unavailable for this variant, which is reported at a frequency of 0.00011 in the European (non-Finnish) population of the Exome Aggregation Consortium. Kaul et al. (1994) demonstrated a complete loss of ASPA activity when the p.Tyr231Ter variant was expressed in COS-1 cells. Based on the collective evidence, the p.Tyr231Ter variant is classified as pathogenic for Canavan disease. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Mar 17, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 29, 2024 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jul 14, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 08, 2022 | Expression studies found that this variant causes complete loss of enzyme activity (Kaul et al., 1994); Nonsense variant in the C-terminus predicted to result in protein truncation, as the last 83 amino acids are lost, and other loss-of-function variants have been reported downstream in the Human Gene Mutation Database (HGMD); This variant is associated with the following publications: (PMID: 21228398, 25525159, 27535533, 25668701, 8023850) - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 13, 2023 | The c.693C>A (p.Y231*) alteration, located in exon 5 (coding exon 5) of the ASPA gene, consists of a C to A substitution at nucleotide position 693. This changes the amino acid from a tyrosine (Y) to a stop codon at amino acid position 231. This alteration occurs at the 3' terminus of the ASPA gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 26% of the protein. However, premature stop codons are typically deleterious in nature, a significant portion of the protein is affected, and the impacted region is critical for protein function (Ambry internal data). Based on data from gnomAD, the A allele has an overall frequency of 0.005% (15/282702) total alleles studied. The highest observed frequency was 0.135% (14/10368) of Ashkenazi Jewish alleles. This alteration was detected in the homozygous state, and in conjunction with another alteration in ASPA, in multiple individuals with Canavan Disease (Kaul, 1994; Yaron, 2005; Nguyen, 2015). In an in vitro assay testing ASPA function, this variant was reported as not expressing any measurable activity (Kaul, 1994). Based on the available evidence, this alteration is classified as pathogenic. - |
Canavan Disease, Familial Form Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 06, 2016 | Variant summary: The ASPA c.693C>A variant is a nonsense mutation resulting in a premature termination codon. It is predicted to cause a truncated or absent ASPA protein, which is a commonly known mechanism for disease. Mutation taster predicts damaging outcome for this variant. This variant is found in 7/121216 control chromosomes at a frequency of 0.0000577, which does not exceed maximal expected frequency of a pathogenic allele (0.0079057). It was reported in several Canavan Disease patients in either homozygosity or in compound heterozygosity with pathogenic ASPA alleles indicating pathogenicity. A functional study demonstrated the variant to result in complete loss of ASPA activity, further supporting a disease causing impact In addition, clinical diagnostic laboratories and reputable databases classify variant as Pathogenic. Moreover, the variant is known to account for 14.8% of the disease alleles in Ashkenazi Jewish patients. Taken together, this variant was classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at